ImPrecise Oversight? Cordis Monitoring Gaps Yield Second Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
J&J Cordis says it is developing more "robust" systems and processes for overseeing clinical studies in response to FDA's warning letter faulting the company for sponsor monitoring lapses in its SAPPHIRE trial
You may also be interested in...
Cordis Precise, Guidant Acculink Are First “Approvable” Carotid Stents
Johnson & Johnson/Cordis and Guidant are working to satisfy FDA's remaining conditions for approval of their respective Precise and Acculink carotid stent systems, as outlined in recent "approvable" letters
Cordis Precise, Guidant Acculink Are First “Approvable” Carotid Stents
Johnson & Johnson/Cordis and Guidant are working to satisfy FDA's remaining conditions for approval of their respective Precise and Acculink carotid stent systems, as outlined in recent "approvable" letters
J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
Carotid revascularization with Cordis' Precise stent is a safe alternative to surgery for high-risk patients, although its benefit to asymptomatic patients remains unclear, an FDA panel concluded April 21